GlassScriptPhysician profile
Latasha Shere Garrett
NPI 1962093765
$8,432.04
in general payments reported to CMS, 2019-2025
26 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $2,243 · 2023: $3,673 · 2024: $1,054 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,142.87 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $918.04 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $886.05 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $874.80 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $522.57 | 2021-2024 | Ingrezza |
| Lundbeck LLC | $429.75 | 2021-2023 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $407.63 | 2021-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $393.23 | 2021-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $379.27 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $339.30 | 2021-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $184.95 | 2022-2023 | Quviviq |
| Indivior INC. | $159.84 | 2021-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $120.60 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $102.36 | 2021 | |
| Hydrofera LLC | $61.57 | 2024 | Hydrofera Blue, Hydrofera Blue Ready - Border |
| Corium, LLC | $55.92 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $43.40 | 2022-2023 | Aplenzin |
| Avanir Pharmaceuticals, INC. | $31.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.58 | 2023 | Austedo |
| Neuronetics, INC. | $19.86 | 2021 | |
| Janssen Products, LP | $15.91 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.56 | 2023 | Jornay Pm |
| Tris Pharma INC | $14.48 | 2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latasha Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.